Posts By: Karen Jones

Membership 2020 and donations

The donation rates are remaining the same for 2020 even though we have not had a good year with regards to fundraising income.  We have had no sponsored events at all in 2019.  If you or anyone you knows is/or can do a sponsored event for us please do encourage it.  If you have any fundraising… Read more »

Single Dose of CD45-ADC Resets the Immune System, Delays the Onset of MS in Mice

From Multiple Sclerosis News Today A single dose of CD45-ADC, an investigational targeted therapy being developed to treat different types of autoimmune diseases, is enough to reset the normal function of the body’s immune system in a mouse model of multiple sclerosis (MS), and to delay onset of the disease. Those findings were presented earlier… Read more »

DWP breached advertising standards

Source MS Society: The Advertising Standards Authority (ASA) has upheld our complaint against the Government’s Universal Credit adverts. Formal investigation In June, as part of the Disability Benefits Consortium (DBC), we submitted a complaint to the ASA about the DWP’s advertising campaign in the Metro newspaper. The ads claimed to be a “myth buster” on Universal Credit. But… Read more »

Sativex cost-effective in final NICE guideline on cannabis-based medicines

Source MS Trust: Sativex is a cost-effective treatment for people with MS spasticity according to new guidance published today by NICE(link is external).  This reverses the decision made in draft guidance published earlier this year. The guideline recommends that, providing the local NHS health authority is willing to pay for continued treatment, a 4-week trial of Sativex can be offered to people… Read more »

European drug regulator recommends restricted use of Lemtrada

Source MS Trust: Lemtrada (alemtuzumab) should be restricted to people with highly active relapsing-remitting MS according to a review carried out by the European Medicines Agency’s (EMA) drug safety committee. Highly active relapsing-remitting MS covers people who continue to have relapses despite taking at least one disease-modifying drug (DMD) or if MS is worsening rapidly with at least two… Read more »

Cannabis-based medicines: Two drugs approved for NHS

Source BBC: Two cannabis-based medicines, used to treat epilepsy and multiple sclerosis, have been approved for use by the NHS in England. It follows new guidelines from the drugs advisory body NICE, which looked at products for several conditions. Charities have welcomed the move, although some campaigners who have been fighting for access to the drugs… Read more »

Immersion in virtual reality scenes of the Arctic helps to ease people’s pain

Source Medical Xpress: Watching immersive 360 videos of icy Arctic scenes helps to relieve intense burning pain and could hold hope for treating chronic pain, a small study has found. Scientists from Imperial College London have found that using virtual reality headsets could combat increased sensitivity to pain, by immersing people in scenes of icebergs, frigid oceans and sprawling icescapes…. Read more »